Publication | Closed Access
Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
76
Citations
0
References
2012
Year
Cancer ManagementPathologyRadium-223 ChlorideRadiation MedicineOncologyGenitourinary CancerCancer Cell BiologyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyFinal TextPhase IiiAsco Daily NewsCancer TreatmentProstatic DiseaseMalignant DiseaseUrologyTumoral PathologyMultinational StudyMedicine
LBA4512 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.